Companies Dominating the RNase Control Landscape
- Thermo Fisher Scientific
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- QIAGEN
- Merck & Co.
- Beyotime
- NEB
- Promega
- BioVision
- Rockland Immunochemicals
- AG Scientific
- Jena Bioscience
- Eli Lilly and Company
- Ginkgo Bioworks
- Carver Biosciences, Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Merck & Co. partnered with a biotechnology company, Orna Therapeutics to find, create, and market cancer and infectious illness vaccines and treatments. Furthermore, by this partnership, Orna Therapeutics intends to maintain ownership of its oRNA-LNP technology platform and pursue further development of programs related to genetic diseases and oncology.
- Eli Lilly and Company announced a collaboration with ProQR Therapeutics N.V. to utilize ProQR's unique Axiomer RNA editing platform to identify, create, and market novel genetic medications and investigate further uses for the Axiomer platform to provide patients with illnesses that have a high unmet medical need.
